HomeQuestion

How would you approach therapy for a SMARCA4-deficient undifferentiated sarcoma with isolated involvement of a mediastinal lymph node?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How do you determine your next line of therapy In ALK+ metastatic NSCLC patients who have widespread progression on first-line lorlatinib?

Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?

What are your treatment options and preferences for classical EGFR mutated NSCLC upon widespread progression following first line chemo/osimertinib?

In patients with resected stage II-III NSCLC, who completed adjuvant carboplatin and pemetrexed and are PD-L1 high, which immunotherapy would you offer?

Would you give consolidation durvalumab to a patient who underwent chemoradiation for his stage III NSCLC and is being started on antifibrotic therapy by pulmonology for his ILD?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.